Company Overview and News

5
HighPoint Resources: Undervalued With High Production Growth Potential

2018-09-12 seekingalpha
HighPoint Resources has guided for 77% production growth in FY19 as compared to FY18 and I believe that strong production is likely to trigger stock upside.
PDCE BBG HPR BCEI

5
Bonanza Creek Energy: From Bankruptcy To Bonanza Returns Potential

2018-09-04 seekingalpha
Mid-Continent asset sale in August 2018 has unlocked significant liquidity for accelerated production growth in core asset.
PDCE BCEI

5
Colorado’s bid to block drilling activity muddies political lines

2018-08-23 worldoil
DENVER (Bloomberg) -- Colorado’s Democratic candidate for governor once bankrolled efforts to restrict fracing. Now, he’s working hard to reassure the state’s oil explorers that he’s on their side.
DCP PDCE SRCI HPR TEP

5
PDC Energy (PDCE) Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha
Greetings, and welcome to the PDC Energy 2018 Second Quarter Earnings Call. At this time, everyone is listen-only mode.
DCP PDCE

7
A Major Setback Looms For Colorado Shale

2018-08-09 oilprice
Nick Cunningham is a freelance writer on oil and gas, renewable energy, climate change, energy policy and geopolitics. He is based in Pittsburgh, PA.
APC NBL PDCE SRCI AEUA

5
PDC Energy, Inc. 2018 Q2 - Results - Earnings Call Slides

2018-08-09 seekingalpha
The following slide deck was published by PDC Energy, Inc. in conjunction with their 2018 Q2 earnings call.
PDCE

5
PDCE / PDC Energy, Inc. FORM 8-K (Current Report)

2018-08-09 sec.gov
Document UNITED STATES
PDCE

5
7
PDC Energy (PDCE) Q2 Earnings and Revenues Lag Estimates

2018-08-08 zacks
PDC Energy (PDCE - Free Report) came out with quarterly earnings of $0.56 per share, missing the Zacks Consensus Estimate of $0.61 per share. This compares to earnings of $0.19 per share a year ago. These figures are adjusted for non-recurring items.
ACTG PDCE FANG

5
PDC Energy Announces 2018 Second Quarter Operating and Financial Results Including Total Production of 9.4 Million Barrels of Oil Equivalent; Updates 2018 Production and Financial Guidance

2018-08-08 globenewswire
DENVER, Aug. 08, 2018 (GLOBE NEWSWIRE) -- PDC Energy, Inc. ("PDC" or the "Company") (NASDAQ: PDCE) today reported its 2018 second quarter operating and financial results, as well as updated its full-year 2018 production and financial guidance.
PDCE

33
Top Analyst Upgrades and Downgrades: Broadcom, CBS, Etsy, Illumina, PulteGroup, SeaWorld, Wynn Resorts, Zillow and More

2018-08-07 247wallst
Stocks were indicated to higher on Tuesday after Monday’s recovery rally. Investors have seen a very strong earnings season, with 80% of the S&P 500 reporting earnings and over 70% exceeding expectations. That said, the volatility in 2018 has created a less rewarding “buy every dip” than had been seen in prior years. Many investors are also trying to decide how they want their investments positioned ahead of the midterm elections and with international trade concerns.
Z OBSV ILMN SEAS ALXN AMAT AVGO WMB MS ETSY ABX CBS ALKS ABX WYNN PDCE CBS.A PHM NBIX CBS.WD ACAD ZG TRI CPV BRCM ALDR ALNY

6
Top Ranked Growth Stocks to Buy for July 31st

2018-07-31 zacks
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, July 31st:
PDCE ARCB PHM UTX

5
5 Companies To Watch As Energy Stocks Surge

2018-07-09 oilprice
Your license and viewing of our content is subject to the disclosures contained after this article.
PDCE

5
PDC Energy Announces Second Quarter 2018 Conference Call – Thursday, August 9, 2018

2018-07-09 globenewswire
DENVER, July 09, 2018 (GLOBE NEWSWIRE) -- PDC Energy, Inc. (“PDC” or the “Company”) (Nasdaq:PDCE) today announced plans to host a conference call to discuss second quarter 2018 results. The Company plans to issue its second quarter 2018 news release after market close on the previous day, followed thereafter by additional materials. The release and materials will be available on the Company’s website, www.
PDCE

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 69327R101